Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial - Concepedia

Concepedia

Publication | Open Access

Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial

DOI Full Paper Access

135

Citations

14

References

2021

Year

Lars Erik Kristensen, Mauro Waldemar Keiserman, Kim Papp, Leslie McCasland, Douglas White, Wenjing Lü, Zailong Wang, Ahmed M. Soliman, Ann Eldred, Lisa Barcomb,

Annals of the Rheumatic Diseases

References

	Year	Citations

Page 1